What question did this study set out to answer?

To evaluate the short-term effectiveness of CKD-701 in improving visual outcomes for vitreous hemorrhage due to proliferative diabetic retinopathy.

May 21, 2026BMC Ophthalmology0 citationsOpen Access

Short-term treatment outcomes of the ranibizumab biosimilar CKD-701 for vitreous hemorrhage secondary to proliferative diabetic retinopathy

SYSo Hyun YuKim's Eye Hospital JCJaejin ChoKim's Eye Hospital SPSang Min ParkKim's Eye Hospital

Key Points

To evaluate the short-term effectiveness of CKD-701 in improving visual outcomes for vitreous hemorrhage due to proliferative diabetic retinopathy.
Retrospective analysis of 64 eyes treated with intravitreal CKD-701 injections.
Visual acuity assessed at baseline, first follow-up (mean 3.8 weeks), and 2- and 4-months post-treatment.
Incidence of recurrent vitreous hemorrhage and vitrectomy recorded.
Visual acuity improved significantly from a mean logMAR VA of 1.29 at baseline to 0.73 at 4 months (P < 0.001).
40.6% of patients achieved 20/40 or better visual acuity at 4 months.
Recurrent vitreous hemorrhage was observed in 17.2% of patients, with 12.5% undergoing vitrectomy.

Abstract

PURPOSE: To evaluate the short-term clinical outcomes of CKD-701, a ranibizumab biosimilar, in treating vitreous hemorrhage (VH) secondary to proliferative diabetic retinopathy (PDR). METHODS: This retrospective study included 64 eyes of 64 patients with VH secondary to PDR who received intravitreal CKD-701 injections and were followed for at least four months. Visual acuity (VA) was assessed at baseline, at the first follow-up (mean 3.8 weeks), and at 2- and 4-months post-treatment. The incidences of recurrent VH and vitrectomy were recorded. The factors associated with the degree of visual improvement were analyzed. RESULTS: The patients received a mean of 1.8 ± 0.9 injections. VA significantly improved over time (mean logMAR VA: 1.29 ± 0.82 at baseline, 1.11 ± 0.84 at first follow-up, 0.94 ± 0.81 at 2 months, and 0.73 ± 0.68 at 4 months; P 0.999). Baseline VA was significantly associated with the degree of visual improvement (P = 0.010). No severe ocular complications were observed. CONCLUSIONS: In this short-term study, VH secondary to PDR decreased following CKD-701 treatment and was accompanied by visual improvement. Further well-controlled long-term studies are needed to definitively assess the efficacy of CKD-701.

Perguntar à IA

Bookmark

View Full Paper